Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Bellicum Pharmaceuticals

Nasdaq:BLCM
Snowflake Description

Adequate balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BLCM
Nasdaq
$24M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The last earnings update was 16 days ago. More info.


Add to Portfolio Compare Print
  • Bellicum Pharmaceuticals has significant price volatility in the past 3 months.
BLCM Share Price and Events
7 Day Returns
24.9%
NasdaqGM:BLCM
5.2%
US Biotechs
10.5%
US Market
1 Year Returns
-85.8%
NasdaqGM:BLCM
0%
US Biotechs
-11.5%
US Market
BLCM Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Bellicum Pharmaceuticals (BLCM) 24.9% -40.5% -60.9% -85.8% -96.1% -97.9%
US Biotechs 5.2% -6.5% -8.7% 0% 6.2% -10.4%
US Market 10.5% -15.4% -21.4% -11.5% 5.4% 18.1%
1 Year Return vs Industry and Market
  • BLCM underperformed the Biotechs industry which returned 0% over the past year.
  • BLCM underperformed the Market in United States of America which returned -11.5% over the past year.
Price Volatility
BLCM
Industry
5yr Volatility vs Market
Related Companies

BLCM Value

 Is Bellicum Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Bellicum Pharmaceuticals is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Bellicum Pharmaceuticals has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Bellicum Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is $4.77.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Bellicum Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Bellicum Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:BLCM PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-24.01
NasdaqGM:BLCM Share Price ** NasdaqGM (2020-03-27) in USD $4.77
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.4x
United States of America Market PE Ratio Median Figure of 2,939 Publicly-Listed Companies 12.96x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Bellicum Pharmaceuticals.

NasdaqGM:BLCM PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:BLCM Share Price ÷ EPS (both in USD)

= 4.77 ÷ -24.01

-0.2x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Bellicum Pharmaceuticals is loss making, we can't compare its value to the US Biotechs industry average.
  • Bellicum Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Bellicum Pharmaceuticals's expected growth come at a high price?
Raw Data
NasdaqGM:BLCM PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.2x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
2.4%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.96x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Bellicum Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Bellicum Pharmaceuticals's assets?
Raw Data
NasdaqGM:BLCM PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $-5.23
NasdaqGM:BLCM Share Price * NasdaqGM (2020-03-27) in USD $4.77
United States of America Biotechs Industry PB Ratio Median Figure of 429 Publicly-Listed Biotechs Companies 2.53x
United States of America Market PB Ratio Median Figure of 5,148 Publicly-Listed Companies 1.26x
NasdaqGM:BLCM PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:BLCM Share Price ÷ Book Value per Share (both in USD)

= 4.77 ÷ -5.23

-0.91x

* Primary Listing of Bellicum Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Bellicum Pharmaceuticals has negative assets, we can't compare the value of its assets to the US Biotechs industry average.

Next steps:

  1. Examine Bellicum Pharmaceuticals's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Bellicum Pharmaceuticals's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess Bellicum Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Bellicum Pharmaceuticals has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

BLCM Future Performance

 How is Bellicum Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
2.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Bellicum Pharmaceuticals expected to grow at an attractive rate?
  • Unable to compare Bellicum Pharmaceuticals's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Bellicum Pharmaceuticals's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Bellicum Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:BLCM Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:BLCM Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 2.4%
NasdaqGM:BLCM Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 43.1%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:BLCM Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:BLCM Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 53 58 -83 2
2023-12-31 37 22 -94 2
2022-12-31 22 -26 -91 2
2021-12-31 3 -59 -91 3
2020-12-31 4 -78 -68 4
2020-03-28
NasdaqGM:BLCM Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 7 -78 -112
2019-09-30 2 -85 -111
2019-06-30 3 -83 -102
2019-03-31 1 -81 -100
2018-12-31 1 -75 -98
2018-09-30 1 -67 -93
2018-06-30 1 -68 -92
2018-03-31 0 -69 -93
2017-12-31 0 -73 -92
2017-09-30 0 -75 -90
2017-06-30 0 -69 -84
2017-03-31 0 -62 -76

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Bellicum Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Bellicum Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:BLCM Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Bellicum Pharmaceuticals Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:BLCM Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -9.44 0.79 -19.67 2.00
2023-12-31 -10.26 -1.19 -19.33 2.00
2022-12-31 -11.85 -4.74 -18.96 2.00
2021-12-31 -14.30 -9.09 -18.47 3.00
2020-12-31 -12.59 -10.22 -14.16 4.00
2020-03-28
NasdaqGM:BLCM Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -24.01
2019-09-30 -24.47
2019-06-30 -23.14
2019-03-31 -23.23
2018-12-31 -24.37
2018-09-30 -24.61
2018-06-30 -26.29
2018-03-31 -27.86
2017-12-31 -28.94
2017-09-30 -29.77
2017-06-30 -29.40
2017-03-31 -28.14

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Bellicum Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Bellicum Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Bellicum Pharmaceuticals has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

BLCM Past Performance

  How has Bellicum Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Bellicum Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Bellicum Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Bellicum Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Bellicum Pharmaceuticals's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Bellicum Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Bellicum Pharmaceuticals Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:BLCM Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 7.14 -112.48 29.97
2019-09-30 2.32 -110.72 31.23
2019-06-30 2.51 -102.49 28.99
2019-03-31 1.48 -99.72 26.84
2018-12-31 1.12 -98.04 25.00
2018-09-30 0.74 -92.73 23.08
2018-06-30 0.57 -92.36 20.69
2018-03-31 0.21 -92.65 20.81
2017-12-31 0.19 -91.78 21.05
2017-09-30 0.34 -89.80 20.20
2017-06-30 0.32 -84.09 19.88
2017-03-31 0.42 -76.14 18.57
2016-12-31 0.39 -69.24 16.93
2016-09-30 0.34 -66.15 16.53
2016-06-30 0.28 -61.84 16.16
2016-03-31 0.27 -55.87 14.76
2015-12-31 0.28 -48.55 12.67
2015-09-30 0.26 -106.00 10.86
2015-06-30 0.87 -97.01 8.28
2015-03-31 1.34 -90.33 6.09
2014-12-31 1.78 -85.40 4.34
2014-09-30 2.58 -13.99 3.15
2014-06-30 2.65 -11.78 2.51
2014-03-31 2.29 -9.91 2.59
2013-12-31 1.94 -9.06 1.96

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Bellicum Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Bellicum Pharmaceuticals has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Bellicum Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Bellicum Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Bellicum Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

BLCM Health

 How is Bellicum Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Bellicum Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Bellicum Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Bellicum Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Bellicum Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Bellicum Pharmaceuticals has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Bellicum Pharmaceuticals Company Filings, last reported 2 months ago.

NasdaqGM:BLCM Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 -4.75 36.72 91.03
2019-09-30 22.84 36.49 103.30
2019-06-30 30.31 36.27 56.57
2019-03-31 50.86 36.05 73.48
2018-12-31 68.48 35.83 93.00
2018-09-30 92.46 35.61 112.75
2018-06-30 112.54 35.39 129.38
2018-03-31 66.18 35.17 82.11
2017-12-31 84.65 34.95 98.90
2017-09-30 103.12 30.75 113.08
2017-06-30 122.71 30.53 130.23
2017-03-31 143.12 30.31 147.56
2016-12-31 96.57 20.22 103.77
2016-09-30 113.09 20.08 105.31
2016-06-30 127.49 14.95 105.57
2016-03-31 140.37 14.83 108.27
2015-12-31 152.02 0.00 94.06
2015-09-30 166.11 0.00 113.23
2015-06-30 177.01 0.00 119.30
2015-03-31 185.36 0.00 183.64
2014-12-31 191.64 0.00 191.60
2014-09-30 179.01 35.66 213.47
2014-06-30 13.88 0.60 12.16
2014-03-31 11.77 0.80 11.17
2013-12-31 11.77 0.80 11.17
  • Bellicum Pharmaceuticals has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Bellicum Pharmaceuticals's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Bellicum Pharmaceuticals has sufficient cash runway for 1.2 years based on current free cash flow.
  • Bellicum Pharmaceuticals has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 18.6% each year.
X
Financial health checks
We assess Bellicum Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Bellicum Pharmaceuticals has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

BLCM Dividends

 What is Bellicum Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Bellicum Pharmaceuticals dividends.
If you bought $2,000 of Bellicum Pharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Bellicum Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Bellicum Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:BLCM Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1949 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:BLCM Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Bellicum Pharmaceuticals has not reported any payouts.
  • Unable to verify if Bellicum Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Bellicum Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Bellicum Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Bellicum Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Bellicum Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Bellicum Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

BLCM Management

 What is the CEO of Bellicum Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Rick Fair
COMPENSATION $3,278,125
AGE 50
TENURE AS CEO 3.2 years
CEO Bio

Mr. Richard A. Fair, also known as Rick, serves as Director of Clovis Oncology, Inc since October 11, 2018.served as Chief Executive Officer and President of Bellicum Pharmaceuticals, Inc. since January 31, 2017. Mr. Fair served as Head of Oncology Global Product Strategy and Senior Vice President at Genentech, Inc. until January 31, 2017. Mr. Fair served as Senior Vice President, Therapeutic Head Oncology Global Product Strategy at Genentech, Inc., a subsidiary of Roche Holding AG. He served as Vice President of Sales and Marketing for Targeted Small Molecule Franchise at Genentech, Inc. Mr. Fair led oncology product strategy and global commercialization, overseeing the launch of five new molecular entities, including TECENTRIQ®, the first immunotherapy approval for patients with advanced bladder cancer and numerous line extensions. He also contributed to a substantial expansion of investment into cancer immunotherapy and precision medicine. Previously, he held several commercial leadership positions within Genentech, including franchise leadership with P&L responsibility for its thrombolytics and oral oncolytics businesses. Mr. Fair served as Senior Vice President, Therapeutic Head Oncology Global Product Strategy at Genentech, Inc., a subsidiary of Roche Holding AG. Prior to Genentech, Mr. Fair spent nine years in the pharmaceutical business at Johnson & Johnson, holding leadership roles in marketing, managed care and reimbursement strategy and managed care customer management. He has been Director of Bellicum Pharmaceuticals, Inc. since January 31, 2017. Mr. Fair holds a Bachelor of Science from the University of Michigan and a Masters of Business Administration from Columbia Business School.

CEO Compensation
  • Rick's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Rick's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Bellicum Pharmaceuticals management team in years:

1.8
Average Tenure
47
Average Age
  • The average tenure for the Bellicum Pharmaceuticals management team is less than 2 years, this suggests a new team.
Management Team

Rick Fair

TITLE
President
COMPENSATION
$3M
AGE
50
TENURE
3.2 yrs

Shane Ward

TITLE
Chief Legal & Strategy Officer and Corporate Secretary
COMPENSATION
$1M
AGE
44
TENURE
1.8 yrs

Atabak Mokari

TITLE
Chief Financial Officer
AGE
42
TENURE
1.3 yrs

David Strauss

TITLE
Director
AGE
33
TENURE
0.2 yrs

Alan Smith

TITLE
Executive Vice President of Technical Operations
COMPENSATION
$1M
AGE
61
TENURE
4.4 yrs

Aaron Foster

TITLE
Head of Research & Senior VP
TENURE
1 yrs

Tom Farrell

TITLE
Consultant
COMPENSATION
$2M
AGE
56
TENURE
3.2 yrs
Board of Directors Tenure

Average tenure and age of the Bellicum Pharmaceuticals board of directors in years:

3.5
Average Tenure
57
Average Age
  • The tenure for the Bellicum Pharmaceuticals board of directors is about average.
Board of Directors

James Brown

TITLE
Chairman of the Board
COMPENSATION
$146K
AGE
54
TENURE
5.3 yrs

Rick Fair

TITLE
President
COMPENSATION
$3M
AGE
50
TENURE
3.2 yrs

David Strauss

TITLE
Director
AGE
33
TENURE
0.2 yrs

Reid Huber

TITLE
Independent Director
COMPENSATION
$126K
AGE
47
TENURE
5.4 yrs

Jon Stonehouse

TITLE
Independent Director
COMPENSATION
$129K
AGE
58
TENURE
5.3 yrs

Steve Davis

TITLE
Independent Director
COMPENSATION
$124K
AGE
58
TENURE
4.7 yrs

David Spencer

TITLE
Member of Scientific & Clinical Advisory Board
AGE
57
TENURE
1 yrs

Jim Daly

TITLE
Independent Director
COMPENSATION
$104K
AGE
57
TENURE
3.8 yrs

Judith Klimovsky

TITLE
Independent Director
COMPENSATION
$137K
AGE
61
TENURE
1.3 yrs

Malcom Brenner

TITLE
Member of Scientific & Clinical Advisory Board
TENURE
1 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Bellicum Pharmaceuticals individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
19. Mar 20 Buy Richard Fair Individual 17. Mar 20 17. Mar 20 5,000 $4.00 $19,999
24. Jan 20 Buy Baker Bros. Advisors LP Company 16. Jan 20 22. Jan 20 18,657 $24.72 $402,062
11. Sep 19 Buy Richard Fair Individual 10. Sep 19 10. Sep 19 4,000 $12.50 $50,000
30. Aug 19 Buy Shane Ward Individual 29. Aug 19 29. Aug 19 800 $12.28 $9,822
23. Aug 19 Buy Richard Fair Individual 21. Aug 19 21. Aug 19 2,000 $9.89 $19,780
X
Management checks
We assess Bellicum Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Bellicum Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

BLCM News

Simply Wall St News

What You Must Know About Bellicum Pharmaceuticals, Inc.'s (NASDAQ:BLCM) Beta Value

View our latest analysis for Bellicum Pharmaceuticals What we can learn from BLCM's beta value Given that it has a beta of 1.46, we can surmise that the Bellicum Pharmaceuticals share price has been fairly sensitive to market volatility (over the last 5 years). … If this beta value holds true in the future, Bellicum Pharmaceuticals shares are likely to rise more than the market when the market is going up, but fall faster when the market is going down. … What this means for you: Since Bellicum Pharmaceuticals has a reasonably high beta, it's worth considering why it is so heavily influenced by broader market sentiment.

Simply Wall St -

How Should Investors Feel About Bellicum Pharmaceuticals, Inc.'s (NASDAQ:BLCM) CEO Pay?

We took a group of companies with market capitalizations below US$200m, and calculated the median CEO total compensation to be US$476k. … Thus we can conclude that Rick Fair receives more in total compensation than the median of a group of companies in the same market, and of similar size to Bellicum Pharmaceuticals, Inc.. … We compared the total CEO remuneration paid by Bellicum Pharmaceuticals, Inc., and compared it to remuneration at a group of similar sized companies.

Simply Wall St -

What Kind Of Shareholder Appears On The Bellicum Pharmaceuticals, Inc.'s (NASDAQ:BLCM) Shareholder Register?

View our latest analysis for Bellicum Pharmaceuticals NasdaqGM:BLCM Ownership Summary, July 9th 2019 What Does The Institutional Ownership Tell Us About Bellicum Pharmaceuticals? … As you can see, institutional investors own 49% of Bellicum Pharmaceuticals. … Insider Ownership Of Bellicum Pharmaceuticals While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders.

Simply Wall St -

Investors Who Bought Bellicum Pharmaceuticals (NASDAQ:BLCM) Shares Three Years Ago Are Now Down 85%

Check out our latest analysis for Bellicum Pharmaceuticals With just US$1,482,000 worth of revenue in twelve months, we don't think the market considers Bellicum Pharmaceuticals to have proven its business plan. … For example, they may be hoping that Bellicum Pharmaceuticals comes up with a great new treatment, before it runs out of money. … A Different Perspective Over the last year, Bellicum Pharmaceuticals shareholders took a loss of 81%.

Simply Wall St -

Does Market Volatility Impact Bellicum Pharmaceuticals, Inc.'s (NASDAQ:BLCM) Share Price?

Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market. … Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

What Kind Of Shareholder Appears On The Bellicum Pharmaceuticals, Inc.'s (NASDAQ:BLCM) Shareholder Register?

Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … Companies that used to be publicly owned tend to have lower insider ownership. … Bellicum Pharmaceuticals is not a large company by global standards.

Simply Wall St -

Should You Be Concerned About Bellicum Pharmaceuticals Inc's (NASDAQ:BLCM) Historical Volatility?

Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. … Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility).

Simply Wall St -

Bellicum Pharmaceuticals Inc (NASDAQ:BLCM): Are Analysts Optimistic?

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. … With the latest financial year loss of -US$91.78m and a trailing-twelve month of -US$92.65m, the US$425.73m market-cap amplifies its loss by moving further away from its breakeven target? … In this article, I will touch on the expectations for BLCM’s growth and when analysts expect the company to become profitable.

Simply Wall St -

Market Sentiment Around Loss-Making Bellicum Pharmaceuticals Inc (NASDAQ:BLCM)

Bellicum Pharmaceuticals Inc's (NASDAQ:BLCM): Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. … Many investors are wondering the rate at which BLCM will turn a profit, with the big question being “when will the company breakeven?” I’ve put together a brief outline of industry analyst expectations for BLCM, its year of breakeven and its implied growth rate. … Check out our latest analysis for Bellicum Pharmaceuticals BLCM is bordering on breakeven, according to analysts.

Simply Wall St -

Where Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) Stands In Terms Of Earnings Growth Against Its Industry

Measuring Bellicum Pharmaceuticals Inc's (NASDAQ:BLCM) track record of past performance is a useful exercise for investors. … See our latest analysis for Bellicum Pharmaceuticals Commentary On BLCM's Past Performance I look at the ‘latest twelve-month’ data, which annualizes the latest 6-month earnings release, or some times, the latest annual report is already the most recent financial data. … Each year, for the past five years Bellicum Pharmaceuticals has seen an annual decline in revenue of -49.61%, on average.

Simply Wall St -

BLCM Company Info

Description

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include Rivo-cel that is in Phase II/III clinical trials to improve hematopoietic stem cell transplantation outcomes in the treatment of hematologic malignancies, including leukemias, lymphomas, and inherited blood disorders; and BPX-601, an autologous GoCAR-T product candidate, which is in Phase I/II clinical trials for treating solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also comprise BPX-603, a dual-switch GoCAR-T product candidate to treat solid tumors that express the human epidermal growth factor receptor 2 antigen; BPX-802, a dual switch Go-CAR-T product candidate to treat an antigen expressed in hematological malignancies; and BPX-701, a T cell receptor candidate, which is in Phase I clinical trial for the treatment of malignant cells expressing the preferentially-expressed antigen in melanoma It has collaboration and license agreements with Adaptimmune Therapeutics plc, Ospedale Pediatrico Bambino Gesù, Leiden University Medical Centre, Agensys, Inc., BioVec Pharma, Inc., Leiden University Medical Centre, ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.

Details
Name: Bellicum Pharmaceuticals, Inc.
BLCM
Exchange: NasdaqGM
Founded: 2004
$24,078,444
5,047,892
Website: http://www.bellicum.com
Address: Bellicum Pharmaceuticals, Inc.
Life Science Plaza,
Suite 800,
Houston,
Texas, 77030,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM BLCM Common Stock Nasdaq Global Market US USD 18. Dec 2014
DB BPX Common Stock Deutsche Boerse AG DE EUR 18. Dec 2014
LSE 0HMS Common Stock London Stock Exchange GB USD 18. Dec 2014
BRSE BPX Common Stock Berne Stock Exchange CH CHF 18. Dec 2014
Number of employees
Current staff
Staff numbers
107
Bellicum Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 03:37
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/13
Last earnings filing: 2020/03/12
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.